{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:11:11Z","timestamp":1793211071575,"version":"4.5.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,3,4]],"date-time":"2024-03-04T00:00:00Z","timestamp":1709510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,3,4]],"date-time":"2024-03-04T00:00:00Z","timestamp":1709510400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1007\/s00280-024-04641-z","type":"journal-article","created":{"date-parts":[[2024,3,4]],"date-time":"2024-03-04T06:01:36Z","timestamp":1709532096000},"page":"497-507","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Visceral obesity and sarcopenia as predictors of efficacy and hematological toxicity in patients with metastatic breast cancer treated with CDK 4\/6 inhibitors"],"prefix":"10.1007","volume":"93","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4745-1605","authenticated-orcid":false,"given":"Kadriye Bir","family":"Y\u00fccel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0582-5020","authenticated-orcid":false,"given":"Uguray","family":"Aydos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3835-2741","authenticated-orcid":false,"given":"Osman","family":"S\u00fctc\u00fcoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9980-8397","authenticated-orcid":false,"given":"Atiye Cenay Karab\u00f6rk","family":"K\u0131l\u0131\u00e7","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9235-9592","authenticated-orcid":false,"given":"Nuriye","family":"\u00d6zdemir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8731-9636","authenticated-orcid":false,"given":"Ahmet","family":"\u00d6zet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2844-0959","authenticated-orcid":false,"given":"Ozan","family":"Yaz\u0131c\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,4]]},"reference":[{"key":"4641_CR1","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1007\/s00520-017-3902-6","volume":"26","author":"E Deluche","year":"2018","unstructured":"Deluche E, Leobon S, Desport JC, Venat-Bouvet L, Usseglio J, Tubiana-Mathieu N (2018) Impact of body composition on outcome in patients with early breast cancer. Support Care Cancer 26:861\u2013868. https:\/\/doi.org\/10.1007\/s00520-017-3902-6","journal-title":"Support Care Cancer"},{"key":"4641_CR2","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1111\/obr.12443","volume":"17","author":"GC Chen","year":"2016","unstructured":"Chen GC, Chen SJ, Zhang R, Hidayat K, Qin JB, Zhang YS, Qin LQ (2016) Central obesity and risks of pre- and postmenopausal breast cancer: a dose-response meta-analysis of prospective studies. Obes Rev 17:1167\u20131177. https:\/\/doi.org\/10.1111\/obr.12443","journal-title":"Obes Rev"},{"key":"4641_CR3","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1093\/annonc\/mdx152","volume":"28","author":"R Yerushalmi","year":"2017","unstructured":"Yerushalmi R, Dong B, Chapman JW, Goss PE, Pollak MN, Burnell MJ, Levine MN, Bramwell VHC, Pritchard KI, Whelan TJ, Ingle JN, Shepherd LE, Parulekar WR, Han L, Ding K, Gelmon KA (2017) Impact of baseline BMI and weight change in CCTG adjuvant breast cancer trials. Ann Oncol 28:1560\u20131568. https:\/\/doi.org\/10.1093\/annonc\/mdx152","journal-title":"Ann Oncol"},{"key":"4641_CR4","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1093\/annonc\/mdu042","volume":"25","author":"DSM Chan","year":"2014","unstructured":"Chan DSM, Vieira AR, Aune D, Bandera EV, Greenwood DC, McTiernan A, Navarro Rosenblatt D, Thune I, Vieira R, Norat T (2014) Body mass index and survival in women with breast cancer-systematic literature review and meta-analysis of 82 follow-up studies. Ann Oncol 25:1901\u20131914. https:\/\/doi.org\/10.1093\/annonc\/mdu042","journal-title":"Ann Oncol"},{"key":"4641_CR5","doi-asserted-by":"publisher","first-page":"e1141","DOI":"10.1016\/j.clbc.2018.04.010","volume":"18","author":"WK Cho","year":"2018","unstructured":"Cho WK, Choi DH, Park W, Cha H, Nam SJ, Kim SW, Lee JE, Yu J, Im YH, Ahn JS, Park YH, Kim JY, Ahn S (2018) Effect of body mass index on survival in breast cancer patients according to subtype, metabolic syndrome, and treatment. Clin Breast Cancer 18:e1141\u2013e1147. https:\/\/doi.org\/10.1016\/j.clbc.2018.04.010","journal-title":"Clin Breast Cancer"},{"key":"4641_CR6","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.breast.2018.05.005","volume":"40","author":"L Zewenghiel","year":"2018","unstructured":"Zewenghiel L, Lindman H, Valachis A (2018) Impact of body mass index on the efficacy of endocrine therapy in patients with metastatic breast cancer-a retrospective two-center cohort study. Breast 40:136\u2013140. https:\/\/doi.org\/10.1016\/j.breast.2018.05.005","journal-title":"Breast"},{"key":"4641_CR7","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.critrevonc.2018.06.011","volume":"129","author":"I Trestini","year":"2018","unstructured":"Trestini I, Carbognin L, Monteverdi S, Zanelli S, De Toma A, Bonaiuto C, Nortilli R, Fiorio E, Pilotto S, Di Maio M, Gasbarrini A, Scambia G, Tortora G, Bria E (2018) Clinical implication of changes in body composition and weight in patients with early-stage and metastatic breast cancer. Crit Rev Oncol Hematol 129:54\u201366. https:\/\/doi.org\/10.1016\/j.critrevonc.2018.06.011","journal-title":"Crit Rev Oncol Hematol"},{"key":"4641_CR8","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/j.annonc.2021.05.353","volume":"32","author":"DJ Slamon","year":"2021","unstructured":"Slamon DJ, Neven P, Chia S, Jerusalem G, De Laurentiis M, Im S, Petrakova K, Valeria Bianchi G, Mart\u00edn M, Nusch A, Sonke GS, De la Cruz-Merino L, Beck JT, Ji Y, Wang C, Deore U, Chakravartty A, Zarate JP, Taran T, Fasching PA (2021) Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival. Ann Oncol 32:1015\u20131024. https:\/\/doi.org\/10.1016\/j.annonc.2021.05.353","journal-title":"Ann Oncol"},{"key":"4641_CR9","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41523-018-0097-z","volume":"5","author":"S Johnston","year":"2019","unstructured":"Johnston S, Martin M, Di Leo A, Im SA, Awada A, Forrester T, Frenzel M, Hardebeck MC, Cox J, Barriga S, Toi M, Iwata H, Goetz MP (2019) MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. NPJ Breast Cancer 5:5. https:\/\/doi.org\/10.1038\/s41523-018-0097-z","journal-title":"NPJ Breast Cancer"},{"key":"4641_CR10","doi-asserted-by":"publisher","first-page":"2681","DOI":"10.4161\/cc.21019","volume":"11","author":"EA Hanse","year":"2012","unstructured":"Hanse EA, Mashek DG, Becker JR, Solmonson AD, Mullany LK, Mashek MT, Towle HC, Chau AT, Albrecht JH (2012) Cyclin D1 inhibits hepatic lipogenesis via repression of carbohydrate response element binding protein and hepatocyte nuclear factor 4\u03b1. Cell Cycle 11:2681\u20132690. https:\/\/doi.org\/10.4161\/cc.21019","journal-title":"Cell Cycle"},{"key":"4641_CR11","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.123000","volume":"3","author":"NJ Iqbal","year":"2018","unstructured":"Iqbal NJ, Lu Z, Liu SM, Schwartz GJ, Chua S Jr, Zhu L (2018) Cyclin-dependent kinase 4 is a preclinical target for diet-induced obesity. JCI insight 3:e123000. https:\/\/doi.org\/10.1172\/jci.insight.123000","journal-title":"JCI insight"},{"key":"4641_CR12","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1038\/s41467-018-03451-1","volume":"9","author":"X Hou","year":"2018","unstructured":"Hou X, Zhang Y, Li W, Hu AJ, Luo C, Zhou W, Hu JK, Daniele SG, Wang J, Sheng J, Fan Y, Greenberg AS, Farmer SR, Hu MG (2018) CDK6 inhibits white to beige fat transition by suppressing RUNX1. Nat Commun 9:1023. https:\/\/doi.org\/10.1038\/s41467-018-03451-1","journal-title":"Nat Commun"},{"key":"4641_CR13","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1158\/1055-9965.EPI-17-0200","volume":"26","author":"BJ Caan","year":"2017","unstructured":"Caan BJ, Meyerhardt JA, Kroenke CH, Alexeeff S, Xiao J, Weltzien E, Feliciano EC, Castillo AL, Quesenberry CP, Kwan ML, Prado CM (2017) Explaining the obesity paradox: the association between body composition and colorectal cancer survival (C-SCANS study). Cancer Epidemiol Biomarkers Prev 26:1008\u20131015. https:\/\/doi.org\/10.1158\/1055-9965.EPI-17-0200","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"4641_CR14","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s13244-015-0414-0","volume":"6","author":"C Yip","year":"2015","unstructured":"Yip C, Dinkel C, Mahajan A, Siddique M, Cook GJ, Goh V (2015) Imaging body composition in cancer patients: visceral obesity, sarcopenia and sarcopenic obesity may impact on clinical outcome. Insights Imaging 6:489\u2013497. https:\/\/doi.org\/10.1007\/s13244-015-0414-0","journal-title":"Insights Imaging"},{"key":"4641_CR15","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.clnu.2011.12.011","volume":"31","author":"R Thibault","year":"2012","unstructured":"Thibault R, Genton L, Pichard C (2012) Body composition: why, when and for who? Clin Nutr 31:435\u2013447. https:\/\/doi.org\/10.1016\/j.clnu.2011.12.011","journal-title":"Clin Nutr"},{"key":"4641_CR16","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1158\/0008-5472.CAN-17-3287","volume":"78","author":"BJ Caan","year":"2018","unstructured":"Caan BJ, Cespedes Feliciano EM, Kroenke CH (2018) The importance of body composition in explaining the overweight paradox in cancer\u2014counterpoint. Cancer Res 78:1906\u20131912. https:\/\/doi.org\/10.1158\/0008-5472.CAN-17-3287","journal-title":"Cancer Res"},{"key":"4641_CR17","doi-asserted-by":"publisher","first-page":"11369","DOI":"10.1038\/s41598-018-29825-5","volume":"8","author":"BA Derstine","year":"2018","unstructured":"Derstine BA, Holcombe SA, Ross BE, Wang NC, Su GL, Wang SC (2018) Skeletal muscle cutoff values for sarcopenia diagnosis using T10 to L5 measurements in a healthy US population. Sci Rep 8:11369. https:\/\/doi.org\/10.1038\/s41598-018-29825-5","journal-title":"Sci Rep"},{"key":"4641_CR18","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1017\/S0007114521001446","volume":"127","author":"B Vangelov","year":"2022","unstructured":"Vangelov B, Bauer J, Kotevski D, Smee RI (2022) The use of alternate vertebral levels to L3 in computed tomography scans for skeletal muscle mass evaluation and sarcopenia assessment in patients with cancer: a systematic review. Br J Nutr 127:722\u2013735. https:\/\/doi.org\/10.1017\/S0007114521001446","journal-title":"Br J Nutr"},{"key":"4641_CR19","doi-asserted-by":"publisher","first-page":"4360","DOI":"10.1016\/j.clnu.2021.01.010","volume":"40","author":"G Bahat","year":"2021","unstructured":"Bahat G, Turkmen BO, Aliyev S, Catikkas NM, Bakir B, Karan MA (2021) Cut-off values of skeletal muscle index and psoas muscle index at L3 vertebra level by computerized tomography to assess low muscle mass. Clin Nutr 40:4360\u20134365. https:\/\/doi.org\/10.1016\/j.clnu.2021.01.010","journal-title":"Clin Nutr"},{"key":"4641_CR20","doi-asserted-by":"publisher","first-page":"8075","DOI":"10.7314\/apjcp.2015.16.18.8075","volume":"16","author":"J Chindapasirt","year":"2015","unstructured":"Chindapasirt J (2015) Sarcopenia in cancer patients. Asian Pac J Cancer Prev 16:8075\u20138077. https:\/\/doi.org\/10.7314\/apjcp.2015.16.18.8075","journal-title":"Asian Pac J Cancer Prev"},{"key":"4641_CR21","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/j.clnu.2017.07.010","volume":"37","author":"F Pamoukdjian","year":"2018","unstructured":"Pamoukdjian F, Bouillet T, L\u00e9vy V, Soussan M, Zelek L, Paillaud E (2018) Prevalence and predictive value of pre-therapeutic sarcopenia in cancer patients: a systematic review. Clin Nutr 37:1101\u20131113. https:\/\/doi.org\/10.1016\/j.clnu.2017.07.010","journal-title":"Clin Nutr"},{"key":"4641_CR22","doi-asserted-by":"publisher","first-page":"2920","DOI":"10.1158\/1078-0432.CCR-08-2242","volume":"15","author":"CM Prado","year":"2009","unstructured":"Prado CM, Baracos VE, McCargar LJ, Reiman T, Mourtzakis M, Tonkin K, Mackey JR, Koski S, Pituskin E, Sawyer MB (2009) Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res 15:2920\u20132926. https:\/\/doi.org\/10.1158\/1078-0432.CCR-08-2242","journal-title":"Clin Cancer Res"},{"key":"4641_CR23","doi-asserted-by":"publisher","unstructured":"Deluche E, Lachatre D, Di Palma M, Simon H, Tissot V, Vansteene D, Meingan P, Mohebi A, Lenczner G, Pigneur F, Goldwasser F, Raynard B; SCAN Study Group (2022) Is sarcopenia a missed factor in the management of patients with metastatic breast cancer? Breast 61:84\u201390. https:\/\/doi.org\/10.1016\/j.breast.2021.12.014","DOI":"10.1016\/j.breast.2021.12.014"},{"key":"4641_CR24","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.e13010","volume":"40","author":"D \u00c7a\u011flayan","year":"2022","unstructured":"\u00c7a\u011flayan D, Kocak MZ, Geredeli C, Tatli AM, Karakurt Ery\u0131lmaz M, G\u00f6ksu SS, Araz M, Arta\u00e7 M (2022) The effect of BMI on the outcomes of CDK 4\/6 inhibitor therapy in HR-positive metastatic breast cancer patients. J Clin Oncol 40:e13010. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.e13010","journal-title":"J Clin Oncol"},{"key":"4641_CR25","doi-asserted-by":"publisher","first-page":"S644","DOI":"10.1016\/j.annonc.2022.07.274","volume":"33","author":"M Artac","year":"2022","unstructured":"Artac M, Ca\u011flayan D, Ko\u00e7ak M, Geredeli C, Tatli A, Goksu SS, Ery\u0131lmaz MK, Araz M (2022) The impact of body mass index (BMI) on the progression-free survival of CDK4\/6 inhibitors in metastatic breast cancer patients (MBC). Ann Oncol 33:S644\u2013S645. https:\/\/doi.org\/10.1016\/j.annonc.2022.07.274","journal-title":"Ann Oncol"},{"key":"4641_CR26","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1093\/jnci\/djaa116","volume":"113","author":"MA Franzoi","year":"2021","unstructured":"Franzoi MA, Eiger D, Ameye L, Ponde N, Caparica R, De Angelis C, Brand\u00e3o M, Desmedt C, Di Cosimo S, Kotecki N, Lambertini M, Awada A, Piccart M, Azambuja E (2021) Clinical implications of body mass index in metastatic breast cancer patients treated with abemaciclib and endocrine therapy. J Nat Cancer Inst 113:462\u2013470. https:\/\/doi.org\/10.1093\/jnci\/djaa116","journal-title":"J Nat Cancer Inst"},{"key":"4641_CR27","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s10549-021-06504-0","volume":"192","author":"R Patel","year":"2022","unstructured":"Patel R, Li Z, Zimmerman BS, Fink MY, Wells JD, Zhou X, Ayers K, Redfern A, Newman S, Schadt E, Oh WK, Chen R, Tiersten A (2022) Impact of body mass index on the efficacy of aromatase inhibitors in patients with metastatic breast cancer. Breast Cancer Res Treat 192:313\u2013319. https:\/\/doi.org\/10.1007\/s10549-021-06504-0","journal-title":"Breast Cancer Res Treat"},{"key":"4641_CR28","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s10549-020-05617-2","volume":"181","author":"MA Franzoi","year":"2020","unstructured":"Franzoi MA, Vandeputte C, Eiger D, Caparica R, Brand\u00e3o M, De Angelis C, Hendlisz A, Awada A, Piccart M, de Azambuja E (2020) Computed tomography-based analyses of baseline body composition parameters and changes in breast cancer patients under treatment with CDK 4\/6 inhibitors. Breast Cancer Res Treat 181:199\u2013209. https:\/\/doi.org\/10.1007\/s10549-020-05617-2","journal-title":"Breast Cancer Res Treat"},{"key":"4641_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.987012","volume":"12","author":"E Kripa","year":"2022","unstructured":"Kripa E, Rizzo V, Galati F, Moffa G, Cicciarelli F, Catalano C, Pediconi F (2022) Do body composition parameters correlate with response to targeted therapy in ER+\/HER2- metastatic breast cancer patients? Role of sarcopenia and obesity. Front Oncol 12:987012. https:\/\/doi.org\/10.3389\/fonc.2022.987012","journal-title":"Front Oncol"},{"key":"4641_CR30","doi-asserted-by":"publisher","first-page":"88","DOI":"10.3348\/kjr.2019.0470","volume":"21","author":"HJ Park","year":"2020","unstructured":"Park HJ, Shin Y, Park J, Kim H, Lee IS, Seo DW, Huh J, Lee TY, Park T, Lee J, Kim KW (2020) Development and validation of a deep learning system for segmentation of abdominal muscle and fat on computed tomography. Korean J Radiol 21:88\u2013100. https:\/\/doi.org\/10.3348\/kjr.2019.0470","journal-title":"Korean J Radiol"},{"key":"4641_CR31","doi-asserted-by":"publisher","first-page":"e0222042","DOI":"10.1371\/journal.pone.0222042","volume":"14","author":"J Park","year":"2019","unstructured":"Park J, Gil JR, Shin Y, Won SE, Huh J, You MW, Park HJ, Sung YS, Kim KW (2019) Reliable and robust method for abdominal muscle mass quantification using CT\/MRI: an explorative study in healthy subjects. PLoS ONE 14:e0222042. https:\/\/doi.org\/10.1371\/journal.pone.0222042","journal-title":"PLoS ONE"},{"key":"4641_CR32","doi-asserted-by":"publisher","first-page":"2376","DOI":"10.1007\/s00261-017-1124-5","volume":"42","author":"TE Murray","year":"2017","unstructured":"Murray TE, Williams D, Lee MJ (2017) Osteoporosis, obesity, and sarcopenia on abdominal CT: a review of epidemiology, diagnostic criteria, and management strategies for the reporting radiologist. Abdom Radiol (NY) 42:2376\u20132386. https:\/\/doi.org\/10.1007\/s00261-017-1124-5","journal-title":"Abdom Radiol (NY)"},{"key":"4641_CR33","doi-asserted-by":"publisher","first-page":"7252","DOI":"10.1158\/1078-0432.CCR-04-0713","volume":"10","author":"RL Camp","year":"2004","unstructured":"Camp RL, Dolled-Filhart M, Rimm DL (2004) X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res 10:7252\u20137259. https:\/\/doi.org\/10.1158\/1078-0432.CCR-04-0713","journal-title":"Clin Cancer Res"},{"key":"4641_CR34","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/nrendo.2014.94","volume":"10","author":"J Park","year":"2014","unstructured":"Park J, Morley TS, Kim M, Clegg DJ, Scherer PE (2014) Obesity and cancer\u2014mechanisms underlying tumour progression and recurrence. Nat Rev Endocrinol 10:455\u2013465. https:\/\/doi.org\/10.1038\/nrendo.2014.94","journal-title":"Nat Rev Endocrinol"},{"key":"4641_CR35","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1210\/er.2010-0030","volume":"32","author":"J Park","year":"2011","unstructured":"Park J, Euhus DM, Scherer PE (2011) Paracrine and endocrine effects of adipose tissue on cancer development and progression. Endocr Rev 32:550\u2013570. https:\/\/doi.org\/10.1210\/er.2010-0030","journal-title":"Endocr Rev"},{"key":"4641_CR36","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1002\/cam4.571","volume":"5","author":"T Iwase","year":"2016","unstructured":"Iwase T, Sangai T, Nagashima T, Sakakibara M, Sakakibara J, Hayama S, Ishigami E, Masuda T, Miyazaki M (2016) Impact of body fat distribution on neoadjuvant chemotherapy outcomes in advanced breast cancer patients. Cancer Med 5:41\u201348. https:\/\/doi.org\/10.1002\/cam4.571","journal-title":"Cancer Med"},{"key":"4641_CR37","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1002\/1097-0142(19940715)74:2<632::aid-cncr2820740215>3.0.co;2-t","volume":"74","author":"DV Schapira","year":"1994","unstructured":"Schapira DV, Clark RA, Wolff PA, Jarrett AR, Kumar NB, Aziz NM (1994) Visceral obesity and breast cancer risk. Cancer 74:632\u2013639. https:\/\/doi.org\/10.1002\/1097-0142(19940715)74:2%3c632::aid-cncr2820740215%3e3.0.co;2-t","journal-title":"Cancer"},{"key":"4641_CR38","doi-asserted-by":"publisher","first-page":"159","DOI":"10.3348\/kjr.2020.1475","volume":"23","author":"MR Kwon","year":"2022","unstructured":"Kwon MR, Ko ES, Park MS, Jeong WK, Hwang NY, Kim JH, Lee JE, Kim SW, Yu JH, Han BK, Ko EY, Choi JS, Park KW (2022) Impact of skeletal muscle loss and visceral obesity measured using serial CT on the prognosis of operable breast cancers in asian patients. Korean J Radiol 23:159\u2013171. https:\/\/doi.org\/10.3348\/kjr.2020.1475","journal-title":"Korean J Radiol"},{"key":"4641_CR39","doi-asserted-by":"publisher","unstructured":"Ritter A, Friemel A, Fornoff F, Adjan M, Solbach C, Yuan J, Louwen F (2015) Characterization of adipose-derived stem cells from subcutaneous and visceral adipose tissues and their function in breast cancer cells. Oncotarget 6:34475\u201334493. https:\/\/doi.org\/10.18632\/oncotarget.5922","DOI":"10.18632\/oncotarget.5922"},{"key":"4641_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1758-5996-3-12","volume":"3","author":"CL Donohoe","year":"2011","unstructured":"Donohoe CL, Doyle SL, Reynolds JV (2011) Visceral adiposity, insulin resistance and cancer risk. Diabetol Metab Syndr 3:1\u201313. https:\/\/doi.org\/10.1186\/1758-5996-3-12","journal-title":"Diabetol Metab Syndr"},{"key":"4641_CR41","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1158\/1055-9965.EPI-09-0372","volume":"18","author":"RC Van Kruijsdijk","year":"2009","unstructured":"Van Kruijsdijk RC, Van Der Wall E, Visseren FL (2009) Obesity and cancer: the role of dysfunctional adipose tissue. Cancer Epidemiol Biomarkers Prev 18:2569\u20132578. https:\/\/doi.org\/10.1158\/1055-9965.EPI-09-0372","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"4641_CR42","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s13058-018-1029-4","volume":"20","author":"M Bousquenaud","year":"2018","unstructured":"Bousquenaud M, Fico F, Solinas G, R\u00fcegg C, Santamaria-Mart\u00ednez A (2018) Obesity promotes the expansion of metastasis-initiating cells in breast cancer. Breast Cancer Res 20:104. https:\/\/doi.org\/10.1186\/s13058-018-1029-4","journal-title":"Breast Cancer Res"},{"key":"4641_CR43","doi-asserted-by":"publisher","first-page":"105","DOI":"10.4137\/CMO.S32812","volume":"9","author":"MA Osman","year":"2015","unstructured":"Osman MA, Hennessy BT (2015) Obesity correlation with metastases development and response to first-line metastatic chemotherapy in breast cancer. Clin Med Insights Oncol 9:105\u2013112. https:\/\/doi.org\/10.4137\/CMO.S32812","journal-title":"Clin Med Insights Oncol"},{"key":"4641_CR44","doi-asserted-by":"publisher","first-page":"e11","DOI":"10.5301\/tj.5000515","volume":"102","author":"A Gevorgyan","year":"2016","unstructured":"Gevorgyan A, Bregni G, Galli G, Ganzinelli M, Martinetti A, Lo Vullo S, Mariani L, Festinese F, Sottotetti E, de Braud F, Di Cosimo S (2016) Body mass index and clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer. Tumori 102:e11\u2013e14. https:\/\/doi.org\/10.5301\/tj.5000515","journal-title":"Tumori"},{"key":"4641_CR45","doi-asserted-by":"publisher","unstructured":"Pizzuti L, Natoli C, Gamucci T, Mauri M, Sergi D, Di Lauro L, Paoletti G, Ruggeri E, Iezzi L, Sperduti I, Mentuccia L, Fabbri A, Maugeri-Sacc\u00e0 M, Moscetti L, Barba M, Vici P (2017) Anthropometric, clinical and molecular determinants of treatment outcomes in postmenopausal, hormone receptor positive metastatic breast cancer patients treated with fulvestrant: results from a real word setting. Oncotarget 8:69025\u201369037. https:\/\/doi.org\/10.18632\/oncotarget.16982","DOI":"10.18632\/oncotarget.16982"},{"key":"4641_CR46","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s10549-017-4574-0","volume":"168","author":"HN Rier","year":"2018","unstructured":"Rier HN, Jager A, Sleijfer S, van Rosmalen J, Kock MCJM, Levin MD (2018) Changes in body composition and muscle attenuation during taxane-based chemotherapy in patients with metastatic breast cancer. Breast Cancer Res Treat 168:95\u2013105. https:\/\/doi.org\/10.1007\/s10549-017-4574-0","journal-title":"Breast Cancer Res Treat"},{"key":"4641_CR47","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s40265-020-01461-2","volume":"81","author":"CL Braal","year":"2021","unstructured":"Braal CL, Jongbloed EM, Wilting SM, Mathijssen RHJ, Koolen SLW, Jager A (2021) Inhibiting CDK4\/6 in breast cancer with palbociclib, ribociclib, and abemaciclib: similarities and differences. Drugs 81:317\u2013331. https:\/\/doi.org\/10.1007\/s40265-020-01461-2","journal-title":"Drugs"},{"key":"4641_CR48","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s10549-019-05133-y","volume":"174","author":"F Petrelli","year":"2019","unstructured":"Petrelli F, Ghidini A, Pedersini R, Cabiddu M, Borgonovo K, Parati MC, Ghilardi M, Amoroso V, Berruti A, Barni S (2019) Comparative efficacy of palbociclib, ribociclib and abemaciclib for ER+ metastatic breast cancer: an adjusted indirect analysis of randomized controlled trials. Breast Cancer Res Treat 174:597\u2013604. https:\/\/doi.org\/10.1007\/s10549-019-05133-y","journal-title":"Breast Cancer Res Treat"},{"key":"4641_CR49","first-page":"1545","volume":"12","author":"E Livneh","year":"1996","unstructured":"Livneh E, Shimon T, Bechor E, Doki Y, Schieren I, Bernard I (1996) Linking protein kinase C to the cell cyele: ectopic expression of PKCll NIH3T3 cells alters the expression of cyelins and Cdk inhibitors and induces adipogenesis. Oncogene 12:1545\u20131555","journal-title":"Oncogene"},{"key":"4641_CR50","doi-asserted-by":"publisher","first-page":"21220","DOI":"10.1074\/jbc.M801824200","volume":"283","author":"N Inoue","year":"2008","unstructured":"Inoue N, Yahagi N, Yamamoto T, Ishikawa M, Watanabe K, Matsuzaka T, Nakagawa Y, Takeuchi Y, Kobayashi K, Takahashi A, Suzuki H, Hasty AH, Toyoshima H, Yamada N, Shimano H (2008) Cyclin-dependent kinase inhibitor, p21WAF1\/CIP1, is involved in adipocyte differentiation and hypertrophy, linking to obesity, and insulin resistance. J Biol Chem 283:21220\u201321229. https:\/\/doi.org\/10.1074\/jbc.M801824200","journal-title":"J Biol Chem"},{"key":"4641_CR51","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.ejca.2015.12.030","volume":"57","author":"SS Shachar","year":"2016","unstructured":"Shachar SS, Williams GR, Muss HB, Nishijima TF (2016) Prognostic value of sarcopenia in adults with solid tumours: a meta-analysis and systematic review. Eur J Cancer 57:58\u201367. https:\/\/doi.org\/10.1016\/j.ejca.2015.12.030","journal-title":"Eur J Cancer"},{"key":"4641_CR52","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1177\/0884533616680354","volume":"32","author":"SJ Peterson","year":"2017","unstructured":"Peterson SJ, Mozer M (2017) Differentiating sarcopenia and cachexia among patients with cancer. Nutr Clin Pract 32:30\u201339. https:\/\/doi.org\/10.1177\/0884533616680354","journal-title":"Nutr Clin Pract"},{"key":"4641_CR53","doi-asserted-by":"publisher","first-page":"17105","DOI":"10.1038\/nrdp.2017.105","volume":"4","author":"VE Baracos","year":"2018","unstructured":"Baracos VE, Martin L, Korc M, Guttridge DC, Fearon KCH (2018) Cancer-associated cachexia. Nat Rev Dis Primers 4:17105. https:\/\/doi.org\/10.1038\/nrdp.2017.105","journal-title":"Nat Rev Dis Primers"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-024-04641-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-024-04641-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-024-04641-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T13:02:50Z","timestamp":1713963770000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-024-04641-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,4]]},"references-count":53,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["4641"],"URL":"https:\/\/doi.org\/10.1007\/s00280-024-04641-z","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,4]]},"assertion":[{"value":"8 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. The study was approved by the institutional ethics committee (date: March 21, 2023, no: 05) and conducted in accordance with the related privacy statements and applicable regulatory requirements.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"This study was conducted in accordance with the provisions of the Declaration of Helsinki and its later amendments. Written informed consent was obtained from all patients.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}